



HAL
open science

Review article. Gene therapy, recent developments and future prospects in gastrointestinal oncology.

Yann Touchefeu, Kevin Harrington, Jean Paul Galmiche, Georges Vassaux

► To cite this version:

Yann Touchefeu, Kevin Harrington, Jean Paul Galmiche, Georges Vassaux. Review article. Gene therapy, recent developments and future prospects in gastrointestinal oncology.: Gene therapy, liver neoplasms, colorectal neoplasms, pancreatic neoplasms. *Alimentary Pharmacology and Therapeutics*, 2010, 32 (8), pp.953. 10.1111/j.1365-2036.2010.04424.x . hal-00565917

HAL Id: hal-00565917

<https://hal.science/hal-00565917>

Submitted on 15 Feb 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Review article. Gene therapy, recent developments and future prospects in gastrointestinal oncology.

Journal:	<i>Alimentary Pharmacology & Therapeutics</i>
Manuscript ID:	APT-0320-2010.R1
Wiley - Manuscript type:	Review Article
Date Submitted by the Author:	06-Jul-2010
Complete List of Authors:	Touchefeu, Yann; The Institute of Cancer Research, Targeted Therapy Laboratory, Section of Cell and Molecular Biology Harrington, Kevin; The Institute of Cancer Research, Targeted Therapy Laboratory, Section of Cell and Molecular Biology Galmiche, Jean Paul; Institut des Maladies de l'Appareil Digestif, INSERM U948 Vassaux, Georges; Institut des Maladies de l'Appareil Digestif, INSERM U948
Keywords:	Hepatocellular carcinoma < Hepatology, Colorectal cancer < Disease-based, Pancreatic cancer < Disease-based, Oncology - chemotherapy < Topics, Oncology - radiotherapy < Topics

1
2
3 **Review article. Gene therapy, recent developments and future prospects in**
4
5 **gastrointestinal oncology.**
6
7
8
9

10
11
12 Y. Touchefeu ^{1,2}, K.J. Harrington ², J.P. Galmiche ¹, G. Vassaux ¹
13
14

15 ¹ Institut des Maladies de l'Appareil Digestif, INSERM U948, University Hospital, Nantes,
16
17 France
18

19 ² The Institute of Cancer Research, Targeted Therapy Laboratory, Section of Cell and
20
21 Molecular Biology, London, United Kingdom
22
23
24
25
26
27
28

29 Corresponding author
30

31 Yann Touchefeu
32

33
34 The Institute of Cancer Research, Targeted Therapy Laboratory, Section of Cell and
35
36 Molecular Biology, 237 Fulham Road, London SW3 6JB, United Kingdom
37

38 Email: yann.touchefeu@icr.ac.uk
39
40
41
42

43 Short Title
44

45 Gene therapy, liver neoplasms, colorectal neoplasms, pancreatic neoplasms
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background Gene therapy consists of the introduction of genetic material into cells for a therapeutic purpose. A wide range of gene therapy vectors has been developed and used for applications in gastrointestinal oncology.

Aim To review recent developments and published clinical trials concerning the application of gene therapy in the treatment of liver, colon and pancreatic cancers.

Methods Search of the literature published in English using the PubMed database.

Results A large variety of therapeutic genes are under investigation, such as tumour suppressor, suicide, antiangiogenesis, inflammatory cytokine and micro-RNA genes. Recent progress concerns new vectors, such as oncolytic viruses, and the synergy between viral gene therapy, chemotherapy and radiation therapy. **As evidence of these basic developments, recently-published phase I and II clinical trials, using both single agents and combination strategies, in adjuvant or advanced disease settings, have shown encouraging results and good safety records.**

Conclusion Cancer gene therapy is not yet indicated in clinical practice. However, basic and clinical advances have been reported and gene therapy is a promising, new therapeutic approach for the treatment of gastrointestinal tumours.

INTRODUCTION

Despite recent progress, there is an important need for new therapeutic agents in gastrointestinal oncology. Gene therapy consists of the introduction of genetic material into cells for a therapeutic purpose. The initial aim of the field of gene therapy was the correction of inherited genetic diseases by providing to the targeted cells a functional copy of the deficient gene responsible for the disease. However, gene therapy can also be applied to the treatment of acquired diseases, in particular cancers. Indeed, more than 1500 gene therapy clinical trials have been recorded worldwide and about two thirds of these concern cancers (<http://www.wiley.co.uk/genetherapy/clinical/>). In gastrointestinal oncology, most approaches have targeted liver, colon, and pancreatic tumours, and this review will focus on recent knowledge concerning the use of gene therapy in the treatment of these cancers.

LITERATURE SEARCH

A literature search was performed using the PubMed database, limited to documents published in the English language. Searches were not date-restricted. Search terms included free text words and combinations of the following Mesh terms: [Digestive system neoplasms], [Colorectal Neoplasms], [Liver Neoplasms], [Pancreatic Neoplasms], [Gene Therapy], [Genetic Vectors], [Clinical trial]. The 'Gene Therapy Clinical Trial Worldwide' website was also used to search for clinical trials.

PRINCIPLES OF GENE THERAPY: SELECTION OF A GENE, A VECTOR AND A MANAGEMENT STRATEGY

Selection of the gene

Mutant Gene correction

The principles of gene selection strategies are illustrated in Figure 1. In the case of inherited monogenic diseases, the aim of gene therapy is to transfer and express the defective gene. The situation is more complex in cancer gene therapy because cancer most often results from sequential genetic and epigenetic alterations, affecting oncogenes, tumour-suppressor genes and microRNAs. One gene therapy approach is, thus, to restore tumour-suppressor gene expression or to inhibit oncogene expression. About 11 % of transferred genes in gene therapy clinical trials are tumour-suppressor genes, and many trials have been performed in cancer gene therapy using the p53 gene, mostly including patients with lung or head and neck cancers ([http : //www.wiley.co.uk/genetherapy/clinical/](http://www.wiley.co.uk/genetherapy/clinical/)).

Suicide genes

The aim of suicide gene therapy is to enable, selectively, the transfected cell to transform a prodrug into a toxic metabolite, resulting in cell death. The most widely described suicide gene is the herpes simplex virus thymidine kinase (HSV-tk) gene. HSV-tk can phosphorylate ganciclovir which is a poor substrate for mammalian thymidine kinases. Ganciclovir can, therefore, be transformed into ganciclovir triphosphate which is cytotoxic to the transfected cell, resulting in cell death [1]. This cell death can also affect neighbouring cells which do not express HSV-tk. This phenomenon is called a local bystander effect, as opposed to a bystander effect that can be observed in distant, non-transduced tumour sites [2]. This distant bystander effect involves the immune system.

Immunotherapy

Cancer immunotherapy has been developed to stimulate the immune response against tumour cells. Gene therapy can be used to transfer genes into tumour cells to render them more highly immunogenic. Gene transfer of tumour-specific antigens, co-stimulatory molecules and/or inflammatory cytokines has been assessed. Tumour-associated antigens can be recognised by T lymphocytes. These antigens can be derived from oncogenic viruses (Epstein-Barr virus, human papillomavirus) or can be self-antigens. These self-antigens can be overexpressed antigens or antigens which are altered by virtue of a gene mutation or a post-translational modification. They can also be onco-fetal antigens such as 5T4 antigen and carcinoembryonic antigen (CEA) [3]. Immunisation against a specific antigen can induce cellular and/or humoral immune responses. T-cell activation requires not only the interaction between major histocompatibility molecules bearing a specific peptide and the T-cell receptor, but also non-antigen-specific co-stimulatory activation by interaction of molecules expressed on the T-cell and the antigen presenting cells (such as interactions between CD28 and CTLA-4 expressed on the T-cell, and B7 expressed on the antigen presenting cells). Finally, vectors encoding inflammatory molecule genes (such as interleukin-2, interleukin-12, TNF- α , interferon- γ , GM-CSF) have been engineered. In terms of the site of gene transfer, immunisation can be carried out *in situ* in the tumour or at a distant site [4].

RNA interference

RNA interference is a promising new therapeutic approach for many diseases, including cancer. MicroRNAs (miRNA) are short, endogenous ~22 nucleotide RNAs. They can regulate gene expression at the post-transcriptional level by binding to the 3' untranslated region of the target mRNA, resulting in either mRNA degradation or inhibition of translation [5, 6]. They act as fine-regulators of the proteome [7]. MiRNAs can have oncogenic activities

1
2
3 when they are up-regulated and target tumour suppressor genes [8]. MiRNAs can also have a
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

when they are up-regulated and target tumour suppressor genes [8]. MiRNAs can also have a tumour suppressor potential [9]. Furthermore, miRNAs can modify the response to therapeutic agents. For example, the Let-7 family of miRNAs can modify the response of cancer cells to radiation therapy [10]. The endogenous RNA interference pathway has been exploited to develop other RNA interference molecules: synthetic, exogenous, double-stranded, short, interfering RNA (siRNA) and vectors expressing short hairpin RNAs (shRNA). As opposed to siRNAs, shRNAs are synthesised in the nucleus and use maturation pathways similar to the miRNA maturation pathways [11]. As cancer cells present many well-known RNA interference targets, there are multiple opportunities for therapeutic gene silencing in oncology [12].

The choice of the vector

The effectiveness of gene therapy is highly dependent on the efficacy of gene transfer. The vector has to be safe, has to protect the genetic material from degradation in the extracellular environment, and must release the genetic material to the target cell.

Viral Vectors

Recombinant viruses have been shown to be efficient for gene transfer both *in vitro* and *in vivo*. Many viruses such as adenoviruses, adeno-associated viruses (AAV), retroviruses, lentiviruses, herpes viruses, poxviruses, measles viruses, simian virus 40 recombinant (SV40r) and vesicular stomatitis viruses have been proposed for preclinical studies (Table 1). Other viruses are used as virotherapy, rather than gene therapy, agents, because they cannot be genetically modified (reoviruses) or because they have not been modified with the insertion of a therapeutic transgene. Data and clinical trials related to these

1
2
3 **viruses are not reported in this review.** Viruses can be either replication-defective or
4
5 replication-competent. To engineer replication-defective viruses, one or several genes
6
7 required for viral replication can be deleted. Vectors able to replicate selectively in cancer
8
9 cells would be of great interest in oncology. A new strategy involving so-called “oncolytic”
10
11 viruses has been proposed. In this context, the aim is to generate a pathogen for the tumour,
12
13 which is unable to propagate in, and to harm, normal tissues. Two main characteristics of
14
15 oncolytic viruses are: (1) they replicate selectively in cancer cells and have self-amplification
16
17 properties; (2) they have cancer-cell specific toxicity [13]. Some viruses, such as reoviruses,
18
19 have natural, inherent tumour selectivity [14, 15]. From a general point of view, oncolytic
20
21 viruses can be engineered in three ways. (1) Viruses can be deleted for genes that are
22
23 necessary for their replication in normal cells but not in cancer cells. (2) Another possibility is
24
25 to engineer a virus with genes under the control of a tumour-specific promoter. (3) Viruses
26
27 can also be engineered to bind to specific tumour antigens on the cell surface [13, 16]. In the
28
29 first two approaches, the aim is to restrict the replication of the viruses, while the third
30
31 strategy aims at selective infection of cancer cells. However, viral vectors have many
32
33 limitations. There is a limiting immunogenicity and there are safety considerations, including
34
35 a possible insertional mutagenesis for retroviruses and lentiviruses.
36
37
38
39
40
41
42
43
44

45 **Non-viral Vectors**

46 **Naked DNA**

47
48
49
50 Naked or plasmid DNA has a rapid clearance, and a low cellular uptake. As a
51
52 consequence, the main application of naked DNA injection is in vaccination and
53
54 immunotherapy strategies. Electroporation involves the generation of a transient increase of
55
56 the permeability of cell membranes by the use of electric pulses and is more efficient than a
57
58 simple injection of naked DNA. Electroporation increases the transfer efficiency of drugs,
59
60

1
2
3 DNA or RNA into the cells, *in vitro* and *in vivo* in the case of intratumoural injections [17-
4
5 19]. However, the safety and efficiency of this procedure need to be assessed in humans.

8 **Synthetic vectors**

9
10 Cationic liposomes comprise a lipid bilayer membrane. They are amphiphilic
11 molecules and can interact with negatively-charged DNA, compacting it and protecting it
12 from circulating endonucleases. The structure generated upon incubation of DNA with
13 liposome is called a lipoplex. Cationic lipoplexes can bind to negatively-charged cell
14 membranes and induce cellular uptake. However, *in-vivo* transfer efficiency remains low [20].
15
16
17
18
19
20
21
22
23

24 Blood vessels in tumours can have gaps between endothelial cells, up to 800 nm in
25 size. Nanoparticles can extravasate through these gaps and accumulate selectively in tumours.
26 This enhanced permeability and retention (EPR) effect could explain the tumour selectivity of
27 several gene therapy vectors [21]. Nanoparticles are small-sized vectors which can be
28 lipoplexes, other polymers, or metal- and ceramic-based. They can be used as gene therapy
29 vectors and can accumulate in tumours as a result of the EPR effect [22-23].
30
31
32
33
34
35
36
37

38 **Biological non-viral vectors**

39
40 Bacteria can be used as gene therapy vectors. They can be used as gene transfer
41 vectors or protein delivery systems when the therapeutic transgene is already expressed in the
42 bacterium [24]. In addition, many mammalian cell types can be used as carriers of gene
43 therapy vectors [25]. Haematological and progenitor mesenchymal cells are promising agents
44 for use in cancer gene therapy. For example, cytokine-induced killer (CIK) cells can be
45 obtained from mouse splenocytes or human peripheral blood, after *in-vitro* stimulation and
46 culture with interferon- γ , interleukin-2 and anti-CD3 antibodies. These cells naturally target
47 tumours and have cytotoxic effects. They have been combined with the oncolytic vaccinia
48 virus and a synergistic antitumour effect has been observed in mouse models [26].
49
50
51
52
53
54
55
56
57
58
59
60

Choice of strategy: *in-vivo* versus *ex-vivo*

The *ex-vivo* strategy consists of collecting a cell type or its precursor from the subject, culturing and transducing the cells with the vector and then reintroducing the genetically-modified cells into the subject. The *in-vivo* strategy consists of direct injection of the vector into the subject (either intratumourally or systemically). The *ex-vivo* strategy allows control of the transduction, and limitation of dissemination of the vector. The *in-vivo* strategy does not require a cell culture step but cell targeting and transduction efficiency are more difficult to control.

GENE THERAPY IN GASTROINTESTINAL ONCOLOGY: CLINICAL TRIALS AND FUTURE PROSPECTS

Liver Tumours

Clinical trials

Based on preclinical data, several clinical phase I and phase II trials concerning gene therapy of liver tumours have been published (Table 2) [27-34]. Re-expression of tumour-suppressor genes has been evaluated *in vitro*, *in vivo* and in clinical trials, mainly with vectors encoding wild-type p53. In a recently-published, phase II trial, 46 patients with unresectable hepatocellular carcinoma were randomised to either group 1 (multiple hepatic arterial injections of 5-FU and a recombinant adenovirus encoding the p53 gene, after transcatheter arterial chemoembolisation (TACE)) or group 2 (TACE alone). Both treatments were safe. Partial response or stable disease were reported for 69.5 % of subjects in group 1

1
2
3 and 65.2 % of subjects in group 2. Times to progression were 9.6 months in group 1 and 8.3
4
5 months in group 2. Overall survival times were 12.8 months in group 1 and 10.4 months in
6
7 group 2 [34].
8
9

10
11
12 Other gene therapy trials have concerned suicide therapy strategies. A recent, phase II
13
14 clinical trial compared patients with hepatocellular carcinoma and tumours bigger than 5 cm,
15
16 treated by liver transplantation, with or without adenoviral-mediated HSV-tk therapy. During
17
18 transplantation surgery, adenoviruses encoding HSV-tk were injected into the peritoneal
19
20 cavity around the liver and ganciclovir therapy was started 24 hours after surgery and
21
22 continued for 10 days afterwards. Forty-five patients were included in the trial, 22 received
23
24 liver transplantation only, and 23 received liver transplantation and gene therapy. Recurrence-
25
26 free survival and overall survival were significantly higher in the gene therapy group,
27
28 particularly in patients without vascular invasion before treatment [32].
29
30
31
32
33
34
35

36 A phase I trial included 21 patients (9 patients with primary liver cancers, 5 with
37
38 metastatic colorectal cancers and 7 with pancreatic cancer) in an immunotherapy approach.
39
40 Intratumoural injections of an adenovirus encoding the interleukin 12 gene were well
41
42 tolerated, and a partial, objective remission was observed in 1 patient with hepatocellular
43
44 carcinoma [30]. Another phase I trial included 17 patients (9 patients with primary liver
45
46 cancers, 5 with colorectal cancers and 3 with pancreatic cancer). Patients were treated with
47
48 intratumoural injections of autologous dendritic cells transfected with an adenovirus-encoding
49
50 IL-12 gene. The treatment was well tolerated. It was associated with a marked increase of
51
52 infiltrating CD8+ T lymphocytes in 3 of 11 tumour biopsies analysed. Eleven patients could
53
54 be assessed for response. One partial response was observed in a patient with pancreatic
55
56 carcinoma. Stable disease was observed in two patients and progression in eight patients [31].
57
58
59
60

1
2
3
4
5
6
7 Oncolytic viruses have also been evaluated in clinical trials. In a phase II study, 19
8
9 patients with advanced or metastatic hepatobiliary cancers (tumours of the liver, gall bladder,
10
11 or bile duct) received intratumoural injections of ONYX-015, a first-generation, replication-
12
13 selective adenovirus. Sixteen patients could be evaluated for response. One patient had a
14
15 partial response, one patient had prolonged disease stabilisation (49 weeks), and 8 patients
16
17 had a biological response with a decrease in tumour markers of more than 50 % [28]. Recent
18
19 clinical studies with other therapeutic viruses have been reported, highlighting the interest in
20
21 oncolytic viruses for cancer gene therapy. A phase I trial, including 14 patients with refractory
22
23 primary or metastatic liver tumours, evaluated the maximum tolerated dose of intratumoural
24
25 injection of JX-594. JX-594 is a targeted, oncolytic poxvirus (vaccinia virus) modified by
26
27 disruption of the thymidine kinase gene and insertion of the human granulocyte macrophage
28
29 colony-stimulating factor (GM-CSF). Patients received a mean of 3.4 cycles of intratumoural
30
31 injections. Four patients received only one cycle (2 because of toxicity and 2 because of self-
32
33 withdrawal from the study) and were not analysed for tumour response. Among the 10
34
35 patients analysed, 3 showed a partial response, 6 had stable disease and 1 showed progression
36
37 of disease after CT scan examination. Hyperbilirubinaemia was a limiting factor in patients
38
39 treated with the highest dose. Flu-like symptoms were the most frequent adverse event. Of
40
41 particular interest, JX-594 was found in peripheral blood after the initial injection and delayed
42
43 viraemia was detected several days afterwards. JX-594 was found in non-injected tumours,
44
45 suggesting that the virus could target disseminated tumours after systemic injection [33].
46
47 Another study included 3 patients with concomitant hepatocellular carcinoma and hepatitis B
48
49 virus infection (HBV) with active viral replication. JX-594 intratumoural injections were
50
51 associated with tumour response and a decrease in HBV DNA levels [35].
52
53
54
55
56
57
58
59
60

Perspectives from preclinical models

New strategies aiming at improving the rate of transduction of cells have been developed for gene re-expression strategies, with interesting preclinical results. For example, an adenoviral vector encoding a fusion protein, p53-VP22, has been engineered. VP22 is a herpes simplex virus type 1 tegument protein, exhibiting the capacity to be exported from the cell to neighbouring cells. Some VP22 fusion proteins, such as p53, can retain this capacity. In a model of heterotopic, subcutaneous hepatocellular carcinoma xenograft in mice, intratumoural injections of VP22-p53 adenoviruses were more efficient than those of p53-alone adenoviruses, leading to partial tumour regression [36]. The most widely-described suicide gene is the herpes simplex virus thymidine kinase (HSV-tk) gene. However, other suicide gene strategies have been developed. For example, an adenoviral vector encoding carboxypeptidase G2 (CPG2) has been engineered. CPG2 is an enzyme which catalyses the conversion of alkylating prodrugs such as ZD2767P into cytotoxic agents. Tumour regression was observed in a model of subcutaneous hepatocellular carcinoma xenograft, after intratumoural injection of the vector and treatment with the prodrug, ZD2767P [37]. Other immune therapy strategies have also been evaluated *in vitro*. Adenoviruses encoding CD40 ligand were injected into orthotopic hepatocellular carcinomas in rats. The treatment caused a tumour response, with 10 of 23 treated animals showing a complete response and 9 animals a partial response, and an improved survival of treated rats. The treatment induced lymphocytic infiltration of the tumour, and the tumour response was dependent on CD8⁺ T cells [38]. In a model of alpha-fetoprotein-expressing hepatocellular carcinoma spontaneously developing in mice (BW7756 tumours), the combination of alpha-fetoprotein vaccination (by injection of expression plasmids into muscles) and an adenoviral-mediated chemokine IP-10 and interleukin-12 expression (intratumoural injection) resulted in a synergistic effect with improved survival [39].

1
2
3
4
5
6 The sodium-iodide symporter (NIS) gene encodes a membrane glycoprotein that
7
8 mediates active iodide transport across the basolateral membrane of thyroid follicular cells.
9
10 NIS can drive the uptake of radioisotopes (¹²³Iodide, ¹²⁴Iodide, ¹²⁵Iodide, ¹³¹Iodide,
11
12 ¹⁸⁸Rhenium, ²¹¹Astatine) into the cells [40]. A viral-guided NIS gene therapy is an innovative
13
14 approach of radio-iodine therapy. Such an approach was assessed in a rat model of
15
16 hepatocarcinoma (diethylnitrosamine-treated rats). Animals were treated by intraportal
17
18 injections of an adenovirus encoding rat NIS. Long-term retention of radioiodine was
19
20 demonstrated after viral transduction, both in treated, tumour-bearing rats and in healthy,
21
22 treated rats, but not in control, non-treated rats. After intratumoural injection of the virus,
23
24 intraperitoneal injections of ¹³¹I were associated with inhibition of tumour growth and
25
26 prevention of the formation of new tumour nodules around the injected nodule. Furthermore,
27
28 intraperitoneal injection of the virus followed by ¹³¹I therapy was associated with improved
29
30 survival of diethylnitrosamine-treated rats [41].
31
32
33
34
35
36
37
38

39 New strategies include anti-angiogenic gene therapy and therapeutic RNAi. Anti-
40
41 angiogenic therapies are currently well developed and widely-used in oncology. Endostatin is
42
43 an inhibitor of angiogenesis and tumour growth [42]. An adenovirus encoding human
44
45 endostatin was tested in a model of subcutaneous hepatocellular carcinoma xenograft in mice
46
47 and demonstrated an antitumour effect [43]. Pigment epithelium-derived factor (PEDF) is
48
49 another recently-discovered, anti-angiogenic factor. In a model of heterotopic, subcutaneous
50
51 hepatocellular carcinoma xenograft in mice, intratumoural injections of a plasmid expressing
52
53 PEDF resulted in a significant reduction of tumour volume compared with controls [44].
54
55 Kallistatin is another example of new antiangiogenic inhibitors. Intraportal injections of a
56
57 recombinant AAV encoding kallistatin were performed in hepatic and subcutaneous
58
59
60

1
2
3 hepatocarcinoma murine models. Treatment with the recombinant virus resulted in significant
4
5 tumour growth inhibition, as compared with treatment with empty AAV [45].
6
7
8
9

10
11 There has been recent interest in the RNAi strategy. The pituitary tumour-transforming
12
13 gene 1 (PTTG1) is an oncogene which is frequently expressed in human liver cancers. An
14
15 adenovirus encoding an RNAi targeting PTTG1 (Ad.PTTG1-siRNA) has been engineered. *In*
16
17 *vitro*, the virus could deplete PTTG1 in hepatoma cells, resulting in apoptosis. Furthermore,
18
19 intratumoural injections of the virus led to inhibition of tumour growth in a xenograft tumour
20
21 in mice [46]. Another recent study concerns RNAi cancer gene therapy in a mouse model of
22
23 hepatocellular carcinoma (tet-O-MYC; LAP-tTa). Hepatocellular carcinoma cells exhibit a
24
25 down-regulation of the expression of miR-26a in human and mouse liver tumours. This
26
27 miRNA plays a role in cell cycle arrest. Systemic administration by tail vein injection of an
28
29 adeno-associated virus encoding miR-26a resulted in the inhibition of cancer proliferation,
30
31 with 6 out of 8 treated mice exhibiting only small tumours or no tumour and 6 out of 8 mice
32
33 treated with control virus developing a fulminant disease [47].
34
35
36
37
38
39
40
41
42

43 **Colorectal Cancer**

44 **Clinical trials**

45
46
47
48
49
50
51 Clinical trials concerning the gene therapy of metastatic colorectal cancers have also
52
53 been published (Table 3) [48-55]. Re-expression of tumour-suppressor genes has been
54
55 evaluated in a phase I trial including 17 patients with advanced cancers, among them 5
56
57 patients with colorectal cancer and 1 patient with pancreatic cancer. Patients were treated with
58
59 escalating doses of an adenovirus encoding a wild-type p53 gene (Ad5CMV-p53). The
60

1
2
3 treatment was administered intravenously, daily for 3 consecutive days, every 28 days. There
4
5 were no objective responses; one patient with metastatic and progressive colorectal carcinoma
6
7 had a 10-month period of stable disease. The virus was detectable in plasma 14 and 28 days
8
9 after treatment in the majority of patients treated at the highest dose. Seven patients had
10
11 tumour biopsies before and after treatment. Six of these patients had undetectable Ad5CMV-
12
13 p53 expression before treatment that became detectable after treatment. This study showed
14
15 that this treatment was feasible, with no major toxicity [53].
16
17
18
19
20
21

22 A phase I clinical trial including 16 patients with hepatic metastases from colorectal
23
24 carcinomas assessed the safety of intratumoural injections of an adenovirus encoding the
25
26 HSV-tk gene. Injections were followed by systemic ganciclovir administration. The treatment
27
28 was safe. However, there was no complete or partial tumour response [49].
29
30
31
32
33

34 A p53-specific immunity can be observed in advanced cancers. In a phase I/II, dose-
35
36 escalation trial, 15 patients with advanced colorectal cancers were treated with systemic
37
38 injections of a poxvirus encoding a wild-type p53 gene, aiming to induce p53-specific
39
40 immunity. The treatment could induce p53-specific antibodies and, in 2 out of 5 patients
41
42 treated with the highest dose of virus, a specific T-cell response [51]. TROVAX is a modified
43
44 vaccinia virus encoding the tumour antigen, 5T4, aiming to produce an anti-5T4 immune
45
46 response. Trovax is used in several cancer gene therapy protocols. A phase I/II trial was
47
48 carried out in 22 patients with metastatic colorectal cancer. Repeated intramuscular injections
49
50 of TROVAX were safe and induced an anti-5T4 cellular response. Five out of 22 patients had
51
52 stable disease for a period ranging from 3 to 18 months [54]. A 5T4-specific cellular or
53
54 antibody response was still detectable when given alongside a chemotherapy regimen [56].
55
56
57
58
59
60

1
2
3 A phase II trial included 27 patients with colorectal cancer liver metastases. Infusions
4 of ONYX-015 into the hepatic artery, in combination with 5-FU, were well tolerated with
5 fever, rigors and fatigue as the most common side effects. The antitumoural effect of the virus
6 could not be assessed in patients who had not previously received this chemotherapy regimen.
7
8 Interestingly, 3 patients with 5-FU-refractory disease had a 30-50 % regression of the tumour
9 mass [52]. Another phase I, dose-escalation trial included 12 patients with liver colorectal
10 cancer metastases. All patients were refractory to a first line chemotherapy. NV1020 is an
11 oncolytic herpes simplex virus type 1. Patients had a single NV1020 injection into the hepatic
12 artery at 4 different doses (3 patients in each group). NV1020 administration was well
13 tolerated with fever, rigors and headache as the most common side effects. Antitumour
14 activity was assessed by CT-scan at day 28, even if this was a toxicity study. Two patients had
15 a 39 % and a 20 % reduction, respectively, in tumour size, 7 patients showed stable disease
16 and 3 a progressive disease [55]. Floxuridin chemotherapy was administered after day 28 by
17 an intrahepatic arterial pump, in association with intravenous irinotecan. All 12 patients had a
18 partial response to subsequent chemotherapy [57].
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Perspectives from preclinical models**

42
43 In a recent study, a p53 gene re-expression strategy was improved in a combination of
44 viral-directed therapies. An AAV vector expressing the kringle 1 domain of the human
45 hepatocyte growth factor (AAV-HGFK1) and an adenovirus expressing p53 were combined
46 in a murine model of colorectal cancer xenograft. The combination treatment increased the
47 survival time, inducing apoptosis, necrosis and suppressing angiogenesis, as compared with
48 single agent therapies. *In vitro*, this antiangiogenic effect was related to an inhibitory effect on
49 endothelial cell migration [58].
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The HSV-tk/ganciclovir suicide strategy could also be improved. An adenovirus
4 encoding the monocyte chemoattractant protein-1 (MCP-1) gene has been engineered. In a
5 model of subcutaneous colorectal cell line tumours in immunocompetent mice, intratumoural
6 injections of both MCP-1-encoding adenovirus and of HSV-tk-encoding adenovirus reduced
7 tumour growth significantly more than HSV-tk adenovirus alone [59]. Another suicide system
8 has been developed in a murine model of colorectal cancer. A retrovirus encoding the
9 cytosine deaminase gene was engineered. Cytosine deaminase converts the non-toxic 5-
10 fluorocytosine into toxic 5-fluorouracil. In a model of orthotopic liver metastasis (CT26 cells)
11 in mice, the viral vector was administered into the portal vein *via* intrasplenic injection. 5-
12 fluorocytosine was administered into the peritoneal cavity. All mice in the control groups had
13 tumour progression, but tumour growth was significantly inhibited in the treated mice [60].
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 Chemo-gene and radiation-gene therapies are the combinations of gene therapy with
33 chemotherapy or radiation therapy, respectively. Gene therapy can sensitise colon cancer cells
34 to chemotherapy *in vitro* [61, 62]. Cytosine deaminase (CD) converts 5-fluorocytosine into
35 the toxic metabolite, 5-fluorouracil. Intratumoural injection of free plasmids expressing CD in
36 liver metastasis rat models, in association with an oral treatment with 5-fluorocytosine,
37 resulted in a systemic antitumour effect [63]. Flt3 Ligand (Flt3L) is an activator of dendritic
38 cells and NK cells. Intratumoural injections of an adenovirus encoding Flt3L produced a
39 synergistic effect in association with 5-FU therapy in subcutaneous models of
40 hepatocarcinoma and colon cancer and induced long-term immunity against further parental
41 cancer cell injections [64]. In a recent study, cultured human colorectal cancer cells and
42 tumour xenografts were infected with an engineered adenovirus expressing the NIS gene.
43 Tumour xenografts concentrated ^{99m}Tc Technetium, allowing quantitative imaging by
44 SPECT/CT. NIS expression reached a peak 48 hours after intratumoural injection.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Administration of a single dose of virus combined with a single ¹³¹Iodide dose 48 hours after
4 virus injection induced tumour regression with an additional effect. [65].
5
6
7
8
9

10 Recently, the effect of miRNA targeting c-myc was assessed *in vitro* and *in vivo*. *In*
11 *vitro*, miRNA inhibited c-myc expression, reduced HT 29 cell proliferation and induced
12 apoptosis. *In vivo*, intratumoural injections of miRNA were performed in a model of
13 subcutaneous HT 29 tumour in athymic nude mice. Treatment significantly reduced tumour
14 volume [66]. In another study, a replication-deficient adenovirus expressing p53 and an
15 miRNA targeting the cyclin-dependent kinase inhibitor p 21 (Adp53/mIR-p21) have been
16 engineered. In tumour xenografts in nude mice, intratumoural injections resulted in a
17 significant decrease in tumour volume, as compared with a control virus expressing p53 but
18 not mIR-p21. *In vitro*, Adp53/mIR-p21 increased apoptosis as compared with the control
19 virus, but also increased the sensitivity of cancer cells to doxorubicin [67].
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pancreatic Cancer

Clinical trials

Clinical studies have also been carried out in pancreatic cancer (Table 4) [68-71]. A
phase I study assessed the safety and side effects of a subcutaneous vaccination regimen using
2 viruses (vaccinia virus and fowlpox virus) expressing CEA and mucin-1 with 3 co-
stimulatory molecules (B7.1, ICAM-1 and LFA-3), in association with GM-CSF therapy, in
10 patients with advanced pancreatic cancer. The most common side effects were injection
site reactions, fatigue, headache and nausea. Survival was significantly better in patients who
developed anti-CEA- or anti-MUC-1-specific immune responses; however these are

1
2
3 preliminary data [70]. A phase III study in metastatic pancreatic cancer has been carried out
4
5 (US 635 phase III trial) but results have not yet been published.
6
7
8
9

10 A phase I/II study showed the feasibility and tolerability of endoscopic ultrasound-
11 guided, repeated administrations of the ONYX-015 virus into carcinomas of the pancreas
12 [69]. An interim analysis of the PACT study, a multi-centre, randomised, controlled, phase III
13 clinical trial, was presented at the American Society of Clinical Oncology meeting 2009. The
14 study included 330 patients with advanced pancreatic cancers, with 2 arms of treatment. The
15 control arm received standard, 5-week chemo-radiation therapy, the experimental arm
16 received chemo-radiation plus weekly, intratumoural injections of TNF-eradeTM, an
17 adenovirus encoding the TNF- α gene. Both arms received adjuvant gemcitabine with the
18 option of erlotinib. An interim analysis of overall survival was conducted after the 92nd death
19 (one-third of total expected events) had occurred. The analysis concluded that TNF-eradeTM
20 appeared to be safe and well-tolerated. The overall survival interim analysis indicated a trend
21 in favour of TNF-eradeTM therapy, with a late effect on Kaplan Meyer curves [72].
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Perspectives from preclinical models**

42
43 Transduction efficiency is a major concern in gene therapy. A recently-published
44 study showed high transduction efficiency for gene transfer in cells derived from pancreatic
45 cancers, using a lentiviral vector, both *in vitro* (from 68 to 98 %, depending on the cell line
46 and the multiplicity of infection) and *in vivo*. In tumour xenografts in mice, intratumoural
47 injections of a lentivirus encoding human interferon- β resulted in a significant inhibition of
48 apoptosis [73].
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Peritoneal dissemination is a poor prognostic event in pancreatic cancer.
4
5 Intraperitoneal vector injections may therefore be of great interest. Intraperitoneal injection of
6
7 retrovirus encoding the HSV-tk gene has been effective in treating nude mice with a model of
8
9 metastatic pancreatic cancer disseminated to the peritoneal cavity [74]. The K-ras oncogene is
10
11 mutated in more than 80 % of ductal pancreatic adenocarcinomas [75]. An adenovirus
12
13 expressing K-ras anti-sense RNA can induce apoptosis *in vitro* in human pancreatic cancer
14
15 cells. Intraperitoneal injections of this adenovirus inhibited peritoneal dissemination in
16
17 hamster pancreatic cancer models [76].
18
19
20
21
22
23
24

25 We will focus on the promising approach of chemo- and radiation gene therapy.
26
27 Adenoviruses encoding p53 genes showed a synergistic antitumour effect with 5-FU therapy,
28
29 *in vitro* and *in vivo*, in heterotopic models in rats [77]. A recombinant adenovirus encoding
30
31 deoxycytidine kinase and uridine monophosphate kinase (enzymes converting gemcitabine
32
33 into toxic metabolites) sensitised pancreatic cancer cells to gemcitabine, *in vitro* and in an
34
35 orthotopic tumour hamster model [78]. In a subcutaneous model of pancreatic carcinoma in
36
37 mice, a single, intravenous injection of the vaccinia GLV-1h68 virus, an oncolytic, engineered
38
39 poxvirus, was able to reverse the course of tumour growth. The efficacy of viral therapy was
40
41 enhanced by repeated injections of gemcitabine or cisplatin. Seven out of 8 mice treated with
42
43 the virus and cisplatin had complete tumour regression at the end of the observation period,
44
45 whereas 1 out of 8 mice treated with the virus alone had complete tumour regression. The
46
47 viral therapy was safe, with a high tumour selectivity of the virus after systemic
48
49 administration [79]. Another study demonstrated that an oncolytic virus was able to synergise
50
51 with gemcitabine to kill pancreatic cancer cells *in vitro* and *in vivo* by a synergistic effect on
52
53 apoptotic pathways [80]. In another study, cultured human pancreatic cancer cells and tumour
54
55 xenografts were infected with an engineered measles virus expressing the NIS gene.
56
57
58
59
60

1
2
3 Intratumoural injections resulted in a significant reduction in tumour volume and increased
4 survival time of the treated mice compared with the control mice. Tumour xenografts also
5 concentrated radioiodine, allowing quantitative imaging with ^{123}I micro-SPECT/CT [81].
6
7
8
9
10 Pancreatic cancer is, therefore, a candidate for specific, viral-driven delivery of therapeutic
11 radioisotopes.
12
13
14
15

16 17 CONCLUSION

18
19
20
21
22 The safety profile of gene therapy is a major concern. Recently-published trials have
23 shown good safety records. The most commonly-reported side effects related to treatments
24 involving a viral vector were fever, headache, fatigue, nausea and vomiting. Intratumoural
25 injections were used in most studies. In trials using replication-competent agents, viruses were
26 found in non-injected tumours and regression of both injected and distant disease occurred.
27 This effect could be related to targeting of disseminated tumours by the vector and to local
28 and systemic immune responses. Thus, intratumoural injections could be efficient, even for
29 the treatment of disseminated tumours. However, lesions can be difficult, or impossible, to
30 inject, and repeated intratumoural injections using invasive procedures could be a limiting
31 factor for this approach. Systemic administration has also shown a good safety record, and the
32 development of oncolytic viruses which selectively target tumour cells makes this mode of
33 administration of great interest. These data regarding oncolytic viruses may pave the way for
34 more widespread clinical applications of this approach.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 Gene therapy will need to be positioned in the context of existing cancer therapy
56 strategies. Good safety records could make gene therapy a good candidate in all therapeutic
57 settings (neo-adjuvant, adjuvant, and advanced disease), probably in combination therapies.
58
59
60

1
2
3 Combining gene therapy with chemotherapy or radiation therapy may be very interesting, as
4
5 gene therapy can act as a chemo- or radio-sensitiser, and because chemotherapy and radiation
6
7 therapy can improve gene transfer efficiency and gene expression [82-86].
8
9

10
11
12 Gene therapy is not yet suitable for use in routine clinical practice, mainly because of
13
14 insufficient levels of gene delivery in patients. However, promising preclinical data include
15
16 the recent development of new therapeutic targets, new treatments such as miRNA and new
17
18 vectors and, in particular, vectors that are more highly selective with greater therapeutic
19
20 potential. Clinical trials are ongoing in gastrointestinal cancers, as well as in other tumours
21
22 such as melanoma, brain, head and neck, prostate or ovarian cancers. Even if safety profiles,
23
24 drug-resistance and efficacy have to be elucidated further, cancer gene therapy may become a
25
26 new weapon in anti-cancer strategies.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STATEMENTS OF INTERESTS**Authors' declaration of personal interests:**

KJ Harrington has received unrestricted educational grants in support of laboratory and clinical research from Oncolytics Biotech Inc. and Genelux GmbH.

JP Galmiche has served as a speaker and a consultant for AstraZeneca and Given Imaging.

Declaration of funding interests:

Y Touchefeu has received a doctoral research grant from the Institut National du Cancer.

Part of this work was undertaken in The Royal Marsden NHS Foundation Trust which receives a proportion of its funding from the NHS Executive; the views expressed in this publication are those of the authors and not necessarily those of the NHS Executive. This work was supported by the Institute of Cancer Research, and Cancer Research UK Section of Radiotherapy [CRUK] grant number C46/A10588. We acknowledge NHS funding to the NIHR Biomedical Research Centre. We also acknowledge support from the Institut national de la santé et de la recherche médicale (INSERM).

References

1. Moolten FL, Vonderhaar BK, Mroz PJ. Transduction of the herpes thymidine kinase gene into premalignant murine mammary epithelial cells renders subsequent breast cancers responsive to ganciclovir therapy. *Hum Gene Ther* 1996; 7: 1197-204.
2. Agard C, Ligeza C, Dupas B, *et al.* Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. *Cancer Gene Ther* 2001; 8: 128-36.
3. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. *Lancet* 2009; 373: 673-83.
4. Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. *Cell Res* 2006; 16: 182-8.
5. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. *Mol Cancer Ther* 2008; 7: 3655-60.
6. Vandenoorme TG, Li Y, Philip PA, Sarkar FH. MicroRNA and Cancer: Tiny Molecules with Major Implications. *Curr Genomics* 2008; 9: 97-109.
7. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. *Nature* 2008; 455: 64-71.
8. Gironella M, Seux M, Xie MJ, *et al.* Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. *Proc Natl Acad Sci U S A* 2007; 104: 16170-5.
9. Cimmino A, Calin GA, Fabbri M, *et al.* miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proc Natl Acad Sci U S A* 2005; 102: 13944-9.
10. Weidhaas JB, Babar I, Nallur SM, *et al.* MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. *Cancer Res* 2007; 67: 11111-6.

- 1
2
3 11. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and
4
5 differences. *Adv Drug Deliv Rev* 2009; 61: 746-59.
6
7
- 8 12. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA
9
10 interference therapy for cancer. *Gene Ther* 2006; 13: 464-77.
11
- 12 13. Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. *Gene*
13
14 *Ther* 2008; 15: 877-84.
15
16
- 17 14. Kim M, Chung YH, Johnston RN. Reovirus and tumor oncolysis. *J Microbiol* 2007; 45:
18
19 187-92.
20
21
- 22 15. Thirukkumaran C, Morris DG. Oncolytic viral therapy using reovirus. *Methods Mol Biol*
23
24 2009; 542: 607-34.
25
26
- 27 16. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-
28
29 mechanistic therapeutic class for cancer. *Nat Rev Cancer* 2009; 9: 64-71.
30
31
- 32 17. Favard C, Dean DS, Rols MP. Electrotransfer as a non viral method of gene delivery.
33
34 *Curr Gene Ther* 2007; 7: 67-77.
35
- 36 18. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation-enhanced
37
38 nonviral gene transfer for the prevention or treatment of immunological, endocrine and
39
40 neoplastic diseases. *Curr Gene Ther* 2006; 6: 243-73.
41
42
- 43 19. Mir LM. Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past,
44
45 current, and future. *Mol Biotechnol* 2009; 43: 167-76.
46
47
- 48 20. Tong AW, Jay CM, Senzer N, Maples PB, Nemunaitis J. Systemic therapeutic gene
49
50 delivery for cancer: crafting Paris' arrow. *Curr Gene Ther* 2009; 9: 45-60.
51
52
- 53 21. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy
54
55 and imaging. *CA Cancer J Clin* 2008; 58: 97-110.
56
57
- 58 22. Chisholm EJ, Vassaux G, Martin-Duque P, *et al.* Cancer-specific transgene expression
59
60 mediated by systemic injection of nanoparticles. *Cancer Res* 2009; 69: 2655-62.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23. Klutz K, Russ V, Willhauck MJ, *et al.* Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. *Clin Cancer Res* 2009; 15: 6079-86.
 24. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. *J Pathol* 2006; 208: 290-8.
 25. Power AT, Bell JC. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. *Mol Ther* 2007; 15: 660-5.
 26. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. *Science* 2006; 311: 1780-4.
 27. Habib N, Salama H, Abd El Latif Abu Median A, *et al.* Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. *Cancer Gene Ther* 2002; 9: 254-9.
 28. Makower D, Rozenblit A, Kaufman H, *et al.* Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. *Clin Cancer Res* 2003; 9: 693-702.
 29. Palmer DH, Mautner V, Mirza D, *et al.* Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. *J Clin Oncol* 2004; 22: 1546-52.
 30. Sangro B, Mazzolini G, Ruiz J, *et al.* Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. *J Clin Oncol* 2004; 22: 1389-97.
 31. Mazzolini G, Alfaro C, Sangro B, *et al.* Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. *J Clin Oncol* 2005; 23: 999-1010.

- 1
2
3 32. Li N, Zhou J, Weng D, *et al.* Adjuvant adenovirus-mediated delivery of herpes simplex
4 virus thymidine kinase administration improves outcome of liver transplantation in
5 patients with advanced hepatocellular carcinoma. *Clin Cancer Res* 2007; 13: 5847-54.
6
7
8
9
10 33. Park BH, Hwang T, Liu TC, *et al.* Use of a targeted oncolytic poxvirus, JX-594, in
11 patients with refractory primary or metastatic liver cancer: a phase I trial. *Lancet Oncol*
12 2008; 9: 533-42.
13
14
15
16
17 34. Tian G, Liu J, Zhou JS, Chen W. Multiple hepatic arterial injections of recombinant
18 adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for
19 unresectable hepatocellular carcinoma: a pilot phase II trial. *Anticancer Drugs* 2009; 20:
20 389-95.
21
22
23
24
25
26
27 35. Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594
28 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with
29 hepatocellular carcinoma. *Mol Ther* 2008; 16: 1637-42.
30
31
32
33
34 36. Zender L, Köck R, Eckhard M, *et al.* Gene therapy by intrahepatic and intratumoral
35 trafficking of p53-VP22 induces regression of liver tumors. *Gastroenterology* 2002;
36 123: 608-18.
37
38
39
40
41 37. Schepelmann S, Hallenbeck P, Ogilvie LM, *et al.* Systemic gene-directed enzyme
42 prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with
43 carboxypeptidase G2. *Cancer Res* 2005; 65: 5003-8.
44
45
46
47
48 38. Schmitz V, Barajas M, Wang L, *et al.* Adenovirus-mediated CD40 ligand gene therapy
49 in a rat model of orthotopic hepatocellular carcinoma. *Hepatology* 2001; 34: 72-81.
50
51
52
53 39. Rodríguez MM, Ryu SM, Qian C, *et al.* Immunotherapy of murine hepatocellular
54 carcinoma by alpha-fetoprotein DNA vaccination combined with adenovirus-mediated
55 chemokine and cytokine expression. *Hum Gene Ther* 2008; 19: 753-9.
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
40. Baril P, Martin-Duque P, Vassaux G. Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy. *Br J Pharmacol* 2010; 159: 761–771.
41. Faivre J, Clerc J, Gérolami R, *et al.* Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. *Cancer Res* 2004; 64: 8045-51.
42. O'Reilly MS, Boehm T, Shing Y, *et al.* Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell* 1997; 88: 277-85.
43. Li L, Huang JL, Liu QC, *et al.* Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery. *World J Gastroenterol* 2004; 10: 1867-71.
44. Matsumoto K, Ishikawa H, Nishimura D, Hamasaki K, Nakao K, Eguchi K. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. *Hepatology* 2004; 40: 252-9.
45. Tse LY, Sun X, Jiang H, *et al.* Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. *J Gene Med* 2008; 10: 508-17.
46. Cho-Rok J, Yoo J, Jang YJ, *et al.* Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. *Hepatology* 2006; 43: 1042-52.
47. Kota J, Chivukula RR, O'Donnell KA, *et al.* Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. *Cell* 2009; 137: 1005-17.
48. Rubin J, Galanis E, Pitot HC, *et al.* Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. *Gene Ther* 1997; 4: 419-25.

- 1
2
3 49. Sung MW, Yeh HC, Thung SN, *et al.* Intratumoral adenovirus-mediated suicide gene
4 transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I
5 clinical trial. *Mol Ther* 2001; 4: 182-91.
6
7
8
9
10 50. Reid T, Galanis E, Abbruzzese J, *et al.* Intra-arterial administration of a replication-
11 selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the
12 liver: a phase I trial. *Gene Ther* 2001; 8: 1618-26.
13
14
15
16
17 51. Van der Burg SH, Menon AG, Redeker A, *et al.* Induction of p53-specific immune
18 responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate
19 vaccine. *Clin Cancer Res* 2002; 8: 1019-27.
20
21
22
23
24 52. Reid T, Galanis E, Abbruzzese J, *et al.* Hepatic arterial infusion of a replication-
25 selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical
26 endpoints. *Cancer Res* 2002; 62: 6070-9.
27
28
29
30
31 53. Tolcher AW, Hao D, de Bono J, *et al.* Phase I, pharmacokinetic, and pharmacodynamic
32 study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the
33 wild-type p53 gene, in patients with advanced cancer. *J Clin Oncol* 2006; 24: 2052-8.
34
35
36
37
38 54. Harrop R, Connolly N, Redchenko I, *et al.* Vaccination of colorectal cancer patients
39 with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces
40 immune responses which correlate with disease control: a phase I/II trial. *Clin Cancer*
41 *Res* 2006; 12: 3416-24.
42
43
44
45
46
47
48 55. Kemeny N, Brown K, Covey A, *et al.* Phase I, open-label, dose-escalating study of a
49 genetically engineered herpes simplex virus, NV1020, in subjects with metastatic
50 colorectal carcinoma to the liver. *Hum Gene Ther* 2006; 17: 1214-24.
51
52
53
54
55 56. Harrop R, Drury N, Shingler W, *et al.* Vaccination of colorectal cancer patients with
56 TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is
57
58
59
60

- 1
2
3 safe and induces potent immune responses. *Cancer Immunol Immunother* 2008; 57: 977-
4
5 86
6
7
8 57. Fong Y, Kim T, Bhargava A, *et al.* A herpes oncolytic virus can be delivered via the
9
10 vasculature to produce biologic changes in human colorectal cancer. *Mol Ther* 2009; 17:
11
12 389-94.
13
14
15 58. Nie B, Shen Z, Wen JB, *et al.* AAV-HGFK1 and Ad-p53 cocktail therapy prolongs
16
17 survival of mice with colon cancer. *Mol Cancer Ther* 2008; 7: 2855-65.
18
19
20 59. Kagaya T, Nakamoto Y, Sakai Y, *et al.* Monocyte chemoattractant protein-1 gene
21
22 delivery enhances antitumor effects of herpes simplex virus thymidine
23
24 kinase/ganciclovir system in a model of colon cancer. *Cancer Gene Ther* 2006; 13: 357-
25
26 66.
27
28
29 60. Hiraoka K, Kimura T, Logg CR, *et al.* Therapeutic efficacy of replication-competent
30
31 retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer
32
33 metastasis model. *Cancer Res* 2007; 67: 5345-53.
34
35
36 61. Sabaawy HM, Ikehara S, Adachi Y, *et al.* Enhancement of 5-fluorouracil cytotoxicity on
37
38 human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer. *Int J*
39
40 *Oncol* 1999; 14: 1143-51.
41
42
43 62. Uchida H, Shinoura N, Kitayama J, Watanabe T, Nagawa H, Hamada H. 5-Fluorouracil
44
45 efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in
46
47 DLD-1 colon cancer cells. *J Gene Med* 2003; 5: 287-99.
48
49
50 63. Baqué P, Pierrefite-Carle V, Gavelli A, *et al.* Naked DNA injection for liver metastases
51
52 treatment in rats. *Hepatology* 2002; 35: 1144-52.
53
54
55 64. Hou S, Kou G, Fan X, *et al.* Eradication of hepatoma and colon cancer in mice with
56
57 Flt3L gene therapy in combination with 5-FU. *Cancer Immunol Immunother* 2007; 56:
58
59 1605-13.
60

- 1
2
3 65. Peerlinck I, Merron A, Baril P, *et al.* Targeted radionuclide therapy using a Wnt-
4 targeted replicating adenovirus encoding the Na/I symporter. *Clin Cancer Res* 2009; 15:
5 6595-601.
6
7
8
9
10 66. Zhang X, Ge YL, Tian RH. The knockdown of c-myc expression by RNAi inhibits cell
11 proliferation in human colon cancer HT-29 cells in vitro and in vivo. *Cell Mol Biol Lett*
12 2009; 14: 305-18.
13
14
15 67. Idogawa M, Sasaki Y, Suzuki H, *et al.* A single recombinant adenovirus expressing p53
16 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer
17 cells. *Clin Cancer Res* 2009; 15: 3725-32.
18
19
20 68. Mulvihill S, Warren R, Venook A, *et al.* Safety and feasibility of injection with an E1B-
21 55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary
22 carcinomas of the pancreas: a phase I trial. *Gene Ther* 2001; 8: 308-15.
23
24
25 69. Hecht JR, Bedford R, Abbruzzese JL, *et al.* A phase I/II trial of intratumoral endoscopic
26 ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable
27 pancreatic carcinoma. *Clin Cancer Res* 2003; 9: 555-61.
28
29
30 70. Kaufman HL, Kim-Schulze S, Manson K, *et al.* Poxvirus-based vaccine therapy for
31 patients with advanced pancreatic cancer. *J Transl Med* 2007; 5: 60.
32
33
34 71. Galanis E, Carlson SK, Foster NR, *et al.* Phase I trial of a pathotropic retroviral vector
35 expressing a cytotoxic cyclin G1 construct (Rexin-G) in patients with advanced
36 pancreatic cancer. *Mol Ther* 2008; 16: 979-84.
37
38
39 72. K. J. Chang, W. Fisher, D. Kenady, *et al.* Multicenter randomized controlled phase III
40 clinical trial using TNFerade (TNF) with chemoradiation (CRT) in patients with locally
41 advanced pancreatic cancer (LAPC): Interim analysis (IA) of overall survival (OS)
42 (abstract). *J Clin Oncol* 2009; 27; 4605.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 73. Ravet E, Lulka H, Gross F, Casteilla L, Buscail L, Cordelier P. Using lentiviral vectors
4 for efficient pancreatic cancer gene therapy. *Cancer Gene Ther* 2010; 17: 315-24
5
6
7
8 74. Yang L, Hwang R, Pandit L, Gordon EM, Anderson WF, Parekh D. Gene therapy of
9 metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral
10 herpes simplex thymidine kinase vector supernatant and ganciclovir. *Ann Surg* 1996;
11 224: 405-14.
12
13
14
15
16
17 75. Hruban RH, van Mansfeld AD, Offerhaus GJ, *et al.* K-ras oncogene activation in
18 adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination
19 of mutant-enriched polymerase chain reaction analysis and allele-specific
20 oligonucleotide hybridization. *Am J Pathol* 1993; 143: 545-54.
21
22
23
24
25
26
27 76. Miura Y, Ohnami S, Yoshida K, *et al.* Intraperitoneal injection of adenovirus expressing
28 antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic
29 pancreatic cancer without systemic toxicity. *Cancer Lett* 2005; 218: 53-62.
30
31
32
33
34 77. Eisold S, Linnebacher M, Ryschich E, *et al.* The effect of adenovirus expressing wild-
35 type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer
36 cell lines. *World J Gastroenterol* 2004; 10: 3583-9.
37
38
39
40
41 78. Vernejoul F, Ghénassia L, Souque A, *et al.* Gene therapy based on gemcitabine
42 chemosensitization suppresses pancreatic tumor growth. *Mol Ther* 2006; 14: 758-67.
43
44
45
46 79. Yu YA, Galanis C, Woo Y, *et al.* Regression of human pancreatic tumor xenografts in
47 mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. *Mol*
48 *Cancer Ther* 2009; 8: 141-51.
49
50
51
52
53 80. Leitner S, Sweeney K, Oberg D, *et al.* Oncolytic adenoviral mutants with E1B19K gene
54 deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-
55 tumor efficacy in vivo. *Clin Cancer Res* 2009; 15: 1730-40.
56
57
58
59
60

- 1
2
3 81. Carlson SK, Classic KL, Hadac EM, *et al.* Quantitative molecular imaging of viral
4 therapy for pancreatic cancer using an engineered measles virus expressing the sodium-
5 iodide symporter reporter gene. *AJR Am J Roentgenol* 2009; 192: 279-87.
6
7
8
9
10 82. Zhang M, Li S, Li J, Ensminger WD, Lawrence TS. Ionizing radiation increases
11 adenovirus uptake and improves transgene expression in intrahepatic colon cancer
12 xenografts. *Mol Ther* 2003; 8: 21-8.
13
14
15 83. Egami T, Ohuchida K, Miyoshi K, *et al.* Chemotherapeutic agents potentiate adenoviral
16 gene therapy for pancreatic cancer. *Cancer Sci* 2009; 100: 722-9.
17
18
19
20 84. Egami T, Ohuchida K, Mizumoto K, *et al.* Radiation enhances adenoviral gene therapy
21 in pancreatic cancer via activation of cytomegalovirus promoter and increased
22 adenovirus uptake. *Clin Cancer Res* 2008; 14: 1859-67.
23
24
25
26 85. Hingorani M, White CL, Zaidi S, *et al.* Radiation-mediated up-regulation of gene
27 expression from replication-defective adenoviral vectors: implications for sodium iodide
28 symporter gene therapy. *Clin Cancer Res* 2008; 14: 4915-24.
29
30
31
32
33
34
35
36 86. Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies
37 between radiation and oncolytic viruses. *Curr Opin Mol Ther* 2008; 10: 362-70.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



FIGURE LEGEND

Figure 1. Principles of gene therapy. **A.** Gene re-expression. The vector carries a wild-type version of a mutant gene into the tumour. **B.** Suicide therapy. A combination of the systemic administration of a non-toxic prodrug and the tumour-specific delivery of the prodrug-activating enzyme gene. **C.** Immune therapy. The vector carries a gene encoding a specific immunogenic tumour antigen (1), a co-stimulatory signalling molecule (2) or an inflammatory cytokine (3), leading to immune stimulation. **D.** Oncolytic viruses. Oncolytic viruses specifically replicate in, and kill, tumour cells. **E.** Therapeutic RNA interference. The RNAi (siRNA) or the RNAi gene (shRNA) is delivered into the cell. After maturation and incorporation in the RNA-induced silencing complex (RISC), RNAi can bind an oncogene RNA, leading to oncogene repression and cell death.



Review

Vector	Advantages	Disadvantage
Viral Vectors		
Adenovirus	Large transgene insert capacity Biologically safe	High immunogenicity
Herpes simplex virus	Large transgene insert capacity Availability of anti-herpetic drugs	Immunogenicity
Adeno-associated viruses	Stable transgene expression Reduced immunogenicity	Small transgene insert size capacity Need for helper viruses during manufacture
Retrovirus	Stable transgene expression Only infects dividing cells	Small transgene insert size capacity Possible insertional mutagenesis (integration)
Lentivirus	Infects both dividing and non-dividing cells	Possible insertional mutagenesis (integration)
Vaccinia virus	Long history of safe human use Large transgene insert capacity	High immunogenicity Productive infection in immune suppressed patients Replication in skin lesions (eczema, psoriasis)
Vesicular stomatitis virus	Selective replication-competence in cells with defective interferon response (tumour cells)	High immunogenicity Animal pathogen (safety/environmental concerns)
Measles Virus	Long history of safe human use (Edmonston vaccine strain)	Most adults are immune Wild-type virus is immunosuppressive Rare measles-like illness with vaccine strains
Non-Viral Vectors		
Naked DNA	"Easy" engineering Low immunogenicity	Rapid clearance, low transfection efficiency <i>in vivo</i>
Synthetic vectors	Large gene carrying capacity Nanoparticles can accumulate into tumours as a result of the enhanced permeability and retention effect.	Cationic liposomes have an inflammatory toxicity and a low transfection efficiency <i>in vivo</i>

Table 1. Some advantages and disadvantages of different gene therapy vectors

Author	Clinical phase	Number of patients	Clinical setting	Vector and gene	Treatment Protocol	Comments
Habib et al, 2002 [27]	II Randomised	10	Hepatocellular carcinoma	E1B-deleted adenovirus	Intratumoural ethanol (Group 1) or adenovirus (Group 2) injections	Tumour response assessment: 2 SD and 3 PD in group 1, 1 PR and 4 PD in group 2
Makower et al, 2003 [28]	II	19	Advanced or metastatic hepatobiliary cancer	ONYX-015 adenovirus	Intratumoral injections	Good safety records with two grade 4 toxicities likely related to disease progression Sixteen patients assessed for response: 1 PR, 12 SD, 3 PD
Palmer et al, 2004 [29]	I	18	Resectable primary or metastatic liver cancers	Adenovirus encoding nitroreductase (prodrug activating enzyme)	Intratumoural injection, 3 to 8 days before hepatic resection	Good safety records Transgene expression in the tumour
Sangro et al, 2004 [30]	I	21	Advanced liver, colorectal and pancreatic cancers	IL-12-encoding adenovirus	Intratumoural injections	Good safety records Ninety-nine patients assessed for response at day 30: 1 PR, 10 SD, 8 PD
Mazzolini et al, 2005 [31]	I	17	Nine patients with primary liver tumour, 5 with colorectal cancer, 3 with pancreatic cancers	Autologous dendritic cells transfected with an adenovirus encoding the IL-12 gene	Intratumoural injections	Good safety records 11 patients assessed for response: 1 PR, 2 SD, 8 PD
Li et al, 2007 [32]	II Randomised	45	Hepatocellular carcinoma, adjuvant therapy after liver transplantation	HSV-tk-encoding adenovirus	Group 1: Liver transplantation + postoperative systemic epirubicin injections Group 2: Same procedure + postoperative peritoneal injections of HSV viruses and systemic ganciclovir injections	RFS and OS at 2 years, respectively: 9.1% and 19.9% (Group 1), 43.5% and 69.6% (Group 2)
Park et al, 2008 [33]	I	14	Advanced primary or metastatic liver cancers	Oncolytic vaccinia virus, JX-594	Intratumoural injections	Good safety records 10 patients assessed for response: 3 PR, 6 SD, 1 PD
Tian et al, 2009 [34]	II Randomised	46	Advanced hepatocellular carcinoma, in association with transcatheter arterial chemoembolisation (TACE)	Adenovirus encoding the p53 gene	Group 1: TACE alone Group 2: adenovirus + 5-FU hepatic infusions	OS: 10.4 months (group 1) versus 12.8 months (Group 2)

Table 2. Clinical trials concerning gene therapy in primary liver tumours

PR: Partial Response, SD: Stable Disease, PD: Progressive Disease, RFS: Recurrence Free Survival, OS: Overall Survival

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author	Clinical phase	Number of patients	Clinical setting	Vector and gene	Treatment protocol	Comments
Rubin et al, 1997 [48]	I	15	Advanced colorectal cancers	Liposomal vector, HLA-B7 gene transfer	Intratumoural injections	Good safety record Feasible DNA transfection with gene expression
Sung et al, 2001 [49]	I	16	Advanced colorectal cancers	HSV-tk-encoding adenovirus	Intratumoural injections into liver metastases, followed by systemic ganciclovir administration	Good safety record Tumour response of injected tumour: 11 SD, 5 PD
Reid et al, 2001 [50]	I	11	Advanced colorectal cancers	ONYX-015 adenovirus	Infusions of ONYX-015 into the hepatic artery, in combination with intravenous 5-FU and leucovorin	Good safety record, no dose-limiting toxicity
Van der Burg et al, 2002 [51]	I/II	15	Advanced colorectal cancers	p53-encoding canarypoxvirus	Intravenous injections	Good safety record Induction of p53-specific antibodies and a specific T-cell response with the highest dose of virus
Reid et al, 2002 [52]	II	27	Gastrointestinal carcinoma metastatic to the liver	ONYX-015 adenovirus	Infusions of ONYX-015 into the hepatic artery, in combination with intravenous 5-FU and leucovorin	Three patients with 5-FU refractory disease had a 30-50% tumour regression
Tolcher et al, 2006 [53]	I	17	Advanced cancers, including 5 colorectal and 1 pancreatic cancers	Adenovirus encoding wild -type p53 gene (Ad5CMV-p53)	Intravenous injections	Fever, nausea, vomiting and fatigue were common but rarely severe Tumour response assessment: no objective response, 1 SD.
Harrop et al, 2006 [54]	I/II	22	Advanced colorectal cancers	5T4-encoding vaccinia virus	Intramuscular or intradermal injections	Good safety record Five patients had stable disease for a period ranging from 3 to 18 months
Kemeny et al, 2006 [55]	I	12	Advanced colorectal cancers	NV1020 oncolytic herpes simplex virus	NV1020 injection into the hepatic artery	Good safety record with fever, rigors and headache as most-common adverse effects. Tumour response assessment at Day 28: 2 PR, 7 SD, 3PD


Table 3. Clinical trials concerning gene therapy in metastatic colorectal tumours

PR: Partial Response, SD: Stable Disease, PD: Progressive Disease

Author	Clinical phase	Number of patients	Clinical setting	Vector and gene	Treatment protocol	Comments
Mulvihill et al, 2001 [68]	I	23	Locally advanced cancer	ONYX-015 intratumoural injections	CT-guided injections (n = 22 patients) or intraoperative injections (n = 1) into pancreatic primary tumours every 4 weeks until tumour progression	Good safety record, no clinically significant pancreatitis No detectable viral replication No objective response documented
Hecht et al, 2003 [69]	I/II	21	Locally advanced or metastatic cancer	ONYX-015 intratumoural injections	Endoscopic ultrasound-guided ONYX-015 injections on days 1, 5, 8, 15, 36, 43, 50, and 57, in association with intravenous gemcitabine therapy on days 36, 43, 50, and 57	Two duodenal perforations when transduodenal approach was used. Two instances of sepsis before institution of systematic antibiotic prophylaxis No clinically significant pancreatitis No objective response on day 35 After combined treatment: 2 PR and 8 SD of the targeted lesion
Kaufman et al, 2007 [70]	I	10	Locally advanced or metastatic cancer	Subcutaneous vaccination with vaccinia virus and fowlpox virus, both expressing tumour antigens and co-stimulatory molecules	Subcutaneous vaccination, in association with GM-CSF therapy	Site reaction, fatigue, headache and nausea as most-common side effects Significantly better survival in patients developing anti-CEA or anti-I-specific immune responses
Galanis et al, 2008 [71]	I	12	Gemcitabine-refractory, metastatic pancreatic cancer	Intravenous injections of REX-100, a non replicative, retroviral vector expressing cyclin G1 gene	Repeated intravenous injections	Good safety record No evidence of clinical antitumour activity

Table 4. Clinical trials concerning gene therapy in pancreatic cancer

PR: Partial Response, SD: Stable Disease, PD



Principles of gene therapy. A. Gene re-expression. The vector carries a wild-type version of a mutant gene into the tumour. B. Suicide therapy. A combination of the systemic administration of a non-toxic prodrug and the tumour-specific delivery of the prodrug-activating enzyme gene. C. Immune therapy. The vector carries a gene encoding a specific immunogenic tumour antigen (1), a co-stimulatory signalling molecule (2) or an inflammatory cytokine (3), leading to immune stimulation. D. Oncolytic viruses. Oncolytic viruses specifically replicate in, and kill, tumour cells. E. Therapeutic RNA interference. The RNAi (siRNA) or the RNAi gene (shRNA) is delivered into the cell. After maturation and incorporation in the RNA-induced silencing complex (RISC), RNAi can bind an oncogene RNA, leading to oncogene repression and cell death.

90x109mm (600 x 600 DPI)